Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery

Launched by TONGJI HOSPITAL · Jun 11, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether a drug called Ciprofol can help reduce heart injury after lung surgery done with a minimally invasive technique called video-assisted thoracoscopic surgery (VATS). Heart injury after surgery, even when the surgery isn’t on the heart itself, can happen when the heart doesn’t get enough blood, which can increase risks of serious problems and even death within days or years after surgery. Since Ciprofol is known to keep the heart and blood circulation stable during anesthesia, researchers want to see if using it during these lung surgeries can lower the chances of heart injury afterward.

People who might take part are adults aged 45 to 80 who are scheduled for planned lung surgeries using VATS, such as removing part of the lung or tumors, and who expect to stay in the hospital for at least three days after surgery. Participants will receive general anesthesia during their procedure, and the study will monitor their heart health after surgery. However, people with certain health issues like severe lung disease, unstable heart conditions, allergies to the drug or its ingredients, or who are pregnant or planning to become pregnant soon, would not be eligible. This study is not yet recruiting participants but aims to improve care and safety for patients having these types of lung surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Scheduled for elective video-assisted thoracoscopic (VATS)-assisted thoracic surgery (lobectomy, segmentectomy, wedge resection of two or more lung tissues, mediastinal tumor resection) under general anesthesia;
• • 2. Aged 45 to 80 years (inclusive) at the time of randomization;
• • 3. Expected postoperative hospital stay of ≥3 days;
• • 4. Signed a written informed consent to participate in the study.
• Exclusion Criteria:
• • 1. Patients allergic to propofol, Ciprofol, or analogs of drug excipient components (soybeans, eggs, milk);
• • 2. Patients with unstable angina;
• • 3. Patients with congestive heart failure or hemodynamic instability requiring vasopressor agents;
• • 4. Patients with severe COPD (FEV1 \< 1 L);
• • 5. Glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73m²;
• • 6. Patients with severe hepatic dysfunction (ALT or AST elevation exceeding 1.5 times the upper limit of normal);
• • 7. Male or female patients planning to conceive within the next 3 months;
• • 8. Pregnant or lactating female patients;